JP2021535153A - Ｅｎｐｐ１ポリペプチドおよびその使用方法 - Google Patents

Ｅｎｐｐ１ポリペプチドおよびその使用方法 Download PDF

Info

Publication number
JP2021535153A
JP2021535153A JP2021510864A JP2021510864A JP2021535153A JP 2021535153 A JP2021535153 A JP 2021535153A JP 2021510864 A JP2021510864 A JP 2021510864A JP 2021510864 A JP2021510864 A JP 2021510864A JP 2021535153 A JP2021535153 A JP 2021535153A
Authority
JP
Japan
Prior art keywords
polypeptide
enpp1
subject
seq
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021510864A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535153A5 (https=
Inventor
ポール スタバック
デメトリオス ブラドック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of JP2021535153A publication Critical patent/JP2021535153A/ja
Publication of JP2021535153A5 publication Critical patent/JP2021535153A5/ja
Priority to JP2024165046A priority Critical patent/JP2025000736A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021510864A 2018-08-31 2019-08-31 Ｅｎｐｐ１ポリペプチドおよびその使用方法 Pending JP2021535153A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024165046A JP2025000736A (ja) 2018-08-31 2024-09-24 Ｅｎｐｐ１ポリペプチドおよびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862725607P 2018-08-31 2018-08-31
US62/725,607 2018-08-31
US201962830247P 2019-04-05 2019-04-05
US62/830,247 2019-04-05
PCT/US2019/049243 WO2020047520A1 (en) 2018-08-31 2019-08-31 Enpp1 polypeptides and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024165046A Division JP2025000736A (ja) 2018-08-31 2024-09-24 Ｅｎｐｐ１ポリペプチドおよびその使用方法

Publications (2)

Publication Number Publication Date
JP2021535153A true JP2021535153A (ja) 2021-12-16
JP2021535153A5 JP2021535153A5 (https=) 2022-09-05

Family

ID=69643272

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021510864A Pending JP2021535153A (ja) 2018-08-31 2019-08-31 Ｅｎｐｐ１ポリペプチドおよびその使用方法
JP2024165046A Pending JP2025000736A (ja) 2018-08-31 2024-09-24 Ｅｎｐｐ１ポリペプチドおよびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024165046A Pending JP2025000736A (ja) 2018-08-31 2024-09-24 Ｅｎｐｐ１ポリペプチドおよびその使用方法

Country Status (7)

Country Link
US (2) US12344868B2 (https=)
EP (1) EP3844280A4 (https=)
JP (2) JP2021535153A (https=)
CN (2) CN120383683A (https=)
AU (1) AU2019327572B2 (https=)
CA (1) CA3110498A1 (https=)
WO (1) WO2020047520A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3126839A1 (en) * 2019-01-18 2020-07-23 Inozyme Pharma, Inc. Treatment of diseases involving deficiency of enpp1 or enpp3
KR20230047334A (ko) * 2020-05-27 2023-04-07 이노자임 파마, 인코포레이티드 혈관 평활근 세포 증식을 억제하기 위한 조성물 및 방법
WO2021252549A1 (en) * 2020-06-09 2021-12-16 Inozyme Pharma, Inc. Soluble enpp1 or enpp3 proteins and uses thereof
CA3246877A1 (en) * 2022-03-30 2023-10-05 Yale University METHOD AND COMPOSITIONS FOR THE TREATMENT, ALLEVIATION AND/OR PREVENTION OF DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH)
CN116769718A (zh) * 2023-04-21 2023-09-19 南京逸微健华生物科技有限公司 一种工程化细胞外囊泡及用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005501514A (ja) * 2000-12-12 2005-01-20 メディミューン，インコーポレイテッド 延長した半減期を有する分子ならびにその組成物および用途
JP2018516566A (ja) * 2015-05-19 2018-06-28 イエール ユニバーシティ 病的石灰化状態を治療するための組成物およびそれを使用する方法
WO2018157165A1 (en) * 2017-02-27 2018-08-30 Shattuck Labs, Inc. Methods of making and using extracellular domain-based chimeric proteins

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
WO1995019570A1 (en) 1994-01-14 1995-07-20 Genentech, Inc. Antagonists to insulin receptor tyrosine kinase inhibitor
US6043056A (en) 1998-11-06 2000-03-28 Incyte Pharmaceuticals, Inc. Cell surface glycoproteins
US6521645B2 (en) 2000-11-20 2003-02-18 The University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
US7888372B2 (en) 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
US20020183276A1 (en) 2001-03-23 2002-12-05 Burnham Institute Compositions and methods for modulating bone mineral deposition
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
AU2002324700A1 (en) 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
JP4200100B2 (ja) 2001-11-07 2008-12-24 アジェンシス，インコーポレイテッド 癌の処置および検出において有用な１６１ｐ２ｆ１０ｂと称される、核酸および対応タンパク質
WO2003072593A2 (en) 2002-02-21 2003-09-04 University Of Virginia Patent Foundation Bone targeting peptides
JP5199077B2 (ja) 2005-06-10 2013-05-15 アルタス ファーマシューティカルズ インコーポレイテッド シュウ酸オキシダーゼ結晶の投与による、シュウ酸塩濃度を低下させるための方法
WO2008105911A2 (en) 2006-08-02 2008-09-04 Altus Pharmaceuticals Inc. Crystallized oxalate decarboxylase and methods of use
US20080273206A1 (en) 2007-04-23 2008-11-06 University Of South Carolina Biomimetic Mineralization Method and System
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
US8846603B2 (en) 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins
RU2601154C2 (ru) 2011-03-11 2016-10-27 Синаджива Байофарма Корп Гибридные белки npp1
WO2014126965A2 (en) 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
EP2970940B1 (en) 2013-03-14 2018-07-25 Translate Bio, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
ES2708565T3 (es) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP3967755B1 (en) 2014-12-19 2024-03-27 Inozyme Pharma, Inc. Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
EP3377105A4 (en) 2015-11-20 2019-04-24 Yale University COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
CA3032467A1 (en) 2016-08-05 2018-02-08 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
AU2019267545A1 (en) 2018-05-08 2020-11-26 Yale University Compositions and methods for reducing progression of nephrolithiasis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005501514A (ja) * 2000-12-12 2005-01-20 メディミューン，インコーポレイテッド 延長した半減期を有する分子ならびにその組成物および用途
JP2018516566A (ja) * 2015-05-19 2018-06-28 イエール ユニバーシティ 病的石灰化状態を治療するための組成物およびそれを使用する方法
WO2018157165A1 (en) * 2017-02-27 2018-08-30 Shattuck Labs, Inc. Methods of making and using extracellular domain-based chimeric proteins

Also Published As

Publication number Publication date
CN120383683A (zh) 2025-07-29
AU2019327572B2 (en) 2025-11-13
JP2025000736A (ja) 2025-01-07
CN112930397A (zh) 2021-06-08
EP3844280A4 (en) 2022-09-14
CA3110498A1 (en) 2020-03-05
EP3844280A1 (en) 2021-07-07
WO2020047520A1 (en) 2020-03-05
US12344868B2 (en) 2025-07-01
US20220119782A1 (en) 2022-04-21
CN112930397B (zh) 2025-05-09
US20260049294A1 (en) 2026-02-19
AU2019327572A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
JP2021535153A (ja) Ｅｎｐｐ１ポリペプチドおよびその使用方法
JP6965350B2 (ja) 糖タンパク質再構築のためのエンドグリコシダーゼ変異体及びその使用方法
TW202504930A (zh) 用於糖蛋白工程的糖苷合成酶變體及其使用方法
CA2997263C (en) Apoa-1 fusion polypeptides and related compositions and methods
TW202005979A (zh) 用於t調節細胞之擴展的介白素-2突變蛋白
CA3086178A1 (en) Glycoengineering
AU2022369106B2 (en) Proteins comprising the extracellular domain of p75ntr
KR20250112747A (ko) 향상된 시알릴화를 갖는 변형된 fc 폴리펩티드
JP2024178422A (ja) Ｅｎｐｐ１ポリペプチドおよびその使用方法
TW202434727A (zh) 蛋白酶變異體及其用途
RU2858269C2 (ru) Enpp1 полипептиды и способы их применения
TW202542190A (zh) 包含酸性α—葡萄糖苷酶之融合蛋白及其方法
TW202535925A (zh) 具有增強的Ｆｃ受體結合之Ｆｃ結構域變體

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220826

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240531

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241021